BJP CPD Online e-learning site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCreadie, R. G.
Right arrow Articles by MacDonald, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCreadie, R. G.
Right arrow Articles by MacDonald, I. M.

The British Journal of Psychiatry 131: 310-316 (1977)
© 1977 The Royal College of Psychiatrists

High dosage haloperidol in chronic schizophrenia

RG McCreadie and IM MacDonald

In a double blind chlorpromazine-controlled trial, high dosage haloperidol (100 mg daily) given for three months, appreciably improved the mental state of male chronic 'drug resistant' schizophrenic inpatients in the rehabilitation/long-stay unit of one psychiatric hospital. The results of a three-month follow-up suggested that the improvement could be maintained in some patients on lower doses of the drug. Serious extrapyramidal side effects were not seen at high doses. However, the majority of patients on haloperidol showed a deterioration in ward behaviour, possibly related to drowsiness, and developed raised serum alkaline phosphatase levels. These side effects disappeared in the follow-up period when either the drug was discontinued or the dose of haloperidol reduced.


This article has been cited by other articles:


Home page
 NEJMHome page
J. M. Kane
Schizophrenia
N. Engl. J. Med., January 4, 1996; 334(1): 34 - 42.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
F.W.A. Browne, S.J. Cooper, R. Wilson, and D.J. King
Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients
J Psychopharmacol, January 1, 1988; 2(2): 94 - 103.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1977 The Royal College of Psychiatrists.